MannKind Corporation (MNKD)

Market Cap	1.89B
Revenue (ttm)	267.20M
Net Income (ttm)	21.57M
Shares Out	275.78M
EPS (ttm)	0.08
PE Ratio	86.40
Forward PE	46.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,930,771
Open	6.34
Previous Close	6.30
Day's Range	6.30 - 7.07
52-Week Range	3.17 - 7.63
Beta	1.27
Analysts	Strong Buy
Price Target	8.71 (+27.15%)
Earnings Date	Nov 7, 2024

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertensio...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 28, 2004
• Employees: 414
• Stock Exchange: NASDAQ
• Ticker Symbol: MNKD
• Website: https://www.mannkindcorp.com

Financial Performance

In 2023, MannKind's revenue was $198.96 million, an increase of 99.42% compared to the previous year's $99.77 million. Losses were -$11.94 million, -86.34% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price forecast is $8.71, which is an increase of 27.15% from the latest price.

Price Target

$8.71

(27.15% upside)

Analyst Consensus: Strong Buy